Navigation Links
Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimer's Disease Program
Date:11/15/2013

of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.    Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references relating to the development of CERE-110 for the treatment of Alzheimer's disease and expected timing of data release from the CERE-110 Phase 2 clinical trial. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of CERE-110, ZFNs and ZFP TFs, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo's public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
2. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
3. Sangamo BioSciences Proposes Public Offering Of Common Stock
4. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
5. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
6. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
7. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
8. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
9. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... phylum so full of mean little creatures, the yellow-colored Ormia ... -- at least to crickets. Native to the southeastern U.S. ... sort of parasite. It swoops onto the back of a ... its wicked brood to invade, kill and consume the cricket ... possible without the fly,s ability to find a cricket -- ...
(Date:7/22/2014)... engineering at the University of Texas at Dallas, has ... Texas section of the American Society of Mechanical Engineers ... 158 countries who develop engineering standards and training. They ... the world. , ASME recognized Baughn earlier this year ... Baughn retired as an engineering fellow in 2012 after ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and ... and other markets, announced today that it has closed ... private investors led by Novit L.P., an investment arm ... involved the signing of a Securities Purchase Agreement under ... at a price per share of $1.00, resulting in ...
(Date:7/22/2014)... 22, 2014 The DNA Spectrum ... concise visual representation of history, migration, and culture. ... regaled by family history stories stemming from Europe. His ... "old country." Pictures and 8mm home movies painted an ... the family, and Steve ordered a test from DNA ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4UT Dallas professor receives Engineer of the Year award 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4
... Calif., May 28 CV Therapeutics,Inc. (Nasdaq: ... Nasdaq,marketplace rule 4350, the Company issued new inducement ... hiring, primarily in connection,with its commercialization efforts in ... cover an aggregate 151,800 shares of,common stock and ...
... with research institute to aid in successful mid-career changes, ... Center,( http://www.biocareercenter.com ) an online job board and careers ... Research,Institute who has developed Career Navigator -- a new ... within their fields with success --,to launch this new ...
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Online Career Service Turns Focus to 'Switching Gears' 2SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2
(Date:7/23/2014)... essential fatty acids and energy to infants and ... concern that soybean-based emulsions could compromise immune functions ... Combination lipid emulsions based on triglyceride oil, fish ... address this concern. , However, researchers at Rutgers ... unwarranted, according to a review published today in ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2014. ... million, an increase of 53% compared to $4.4 million in ... income in the second quarter of 2014 was $1.4 million ... The increase in revenue and operating income was driven by ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... (NASDAQ: ABPI) announces evidence that most, if not all ... fungal-induced inflammation as originally proposed by investigators at the ... of the Companys ongoing pivotal Phase 3 clinical trial ... of the antifungal amphotericin B 0.01% suspension. In ...
... most renowned physicists and engineers, OSA,s Frontiers in Optics meeting ... developments in the science of light. What: Frontiers ... 16-20, 2007 Where: Fairmont Hotel, San Jose, Calif. ... A new device that may help give sight to the ...
... great flood of Noahs generation really occur thousands of years ... ancient tsunami" Will pollution levels in our deep seas remain ... of the questions that are being addressed by a new ... non-profit research and education organization, EcoOcean. The team, ...
Cached Biology News:SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma 2Frontiers in Optics presents scientific advancements 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 2TAU scientists probe 'deep' questions aboard EcoOcean's environmental research ship 3
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... A simultaneous dual parameter assay ... poly caspase activity. Active caspases are ... peptide inhibitors, which are cell-permeable, non-cytotoxic ... caspases within the cells. At the ...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: